BioSense, Neovacs Sign $64M Deal for Therapeutic Lupus Vaccine
BioSense Global, a biotech firm, signed a $68 million option agreement with France's Neovacs for China rights to a vaccine aimed to treat systemic lupus erythematosus (SLE, or lupus) and dermatomyositis. The IFNa Kinoid is currently undergoing its Phase II trial.